Acrivon Therapeutics reports progress in Phase 1 trial of ACR-2316.
ByAinvest
Friday, Apr 25, 2025 8:04 am ET1min read
ACRV--
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) has announced the successful completion of three dose-escalation cohorts in its Phase 1 trial of ACR-2316, a novel WEE1/PKMYT1 inhibitor. The company reported solid tumor shrinkage at dose level three, which is well below the projected recommended Phase 2 dose. This promising result was observed in patients with high unmet need solid tumor types predicted to be sensitive to ACR-2316.
The trial, which is enrolling patients with specific high unmet need solid tumor types, has shown drug target engagement already at dose levels 1 and 2, with evidence of dose proportionality. Notably, initial clinical activity, including ~25% RECIST tumor shrinkage and reduction of metastatic lesions, was observed at dose level three.
Acrivon plans to present data from AP3 Generative Phosphoproteomic analyses of ACR-2316-regulated CDK1-, CDK2-, and PLK1-induced pathways at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 25-30, 2025. The presentation will highlight how the company's AP3 platform uncovered the mechanisms underlying ACR-2316's superior preclinical potency and single-agent activity.
The company's chief executive officer, Peter Blume-Jensen, M.D., Ph.D., expressed excitement about the early clinical observations, including the initial activity of ACR-2316. He emphasized that the drug was rationally designed through AP3-based SAR to induce desirable anti-tumor pathway effects and overcome the limitations of single-target WEE1 and PKMYT1 inhibitors.
Acrivon Therapeutics is leveraging its proprietary AP3 precision medicine platform to develop precision oncology medicines. The company is also advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, in a potentially registrational Phase 2 trial for endometrial cancer.
References
[1] https://www.globenewswire.com/news-release/2025/04/25/3068264/0/en/Acrivon-Therapeutics-to-Reveal-the-Molecular-Mechanisms-Driving-Strong-Single-Agent-Activity-of-ACR-2316-its-AP3-Enabled-Clinical-Stage-WEE1-PKMYT1-Inhibitor-at-the-AACR-Annual-Mee.html
Acrivon Therapeutics announced the completion of three dose-escalation cohorts in its Phase 1 trial of ACR-2316. Solid tumor shrinkage has already been observed at dose level three, which is well below the projected recommended Phase 2 dose. The company will present data from AP3 Generative Phosphoproteomic analyses of ACR-2316-regulated CDK1-, CDK2-, and PLK1-induced pathways.
Title: Acrivon Therapeutics Advances Phase 1 Trial of ACR-2316, Demonstrates Early Clinical ActivityAcrivon Therapeutics, Inc. (Nasdaq: ACRV) has announced the successful completion of three dose-escalation cohorts in its Phase 1 trial of ACR-2316, a novel WEE1/PKMYT1 inhibitor. The company reported solid tumor shrinkage at dose level three, which is well below the projected recommended Phase 2 dose. This promising result was observed in patients with high unmet need solid tumor types predicted to be sensitive to ACR-2316.
The trial, which is enrolling patients with specific high unmet need solid tumor types, has shown drug target engagement already at dose levels 1 and 2, with evidence of dose proportionality. Notably, initial clinical activity, including ~25% RECIST tumor shrinkage and reduction of metastatic lesions, was observed at dose level three.
Acrivon plans to present data from AP3 Generative Phosphoproteomic analyses of ACR-2316-regulated CDK1-, CDK2-, and PLK1-induced pathways at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 25-30, 2025. The presentation will highlight how the company's AP3 platform uncovered the mechanisms underlying ACR-2316's superior preclinical potency and single-agent activity.
The company's chief executive officer, Peter Blume-Jensen, M.D., Ph.D., expressed excitement about the early clinical observations, including the initial activity of ACR-2316. He emphasized that the drug was rationally designed through AP3-based SAR to induce desirable anti-tumor pathway effects and overcome the limitations of single-target WEE1 and PKMYT1 inhibitors.
Acrivon Therapeutics is leveraging its proprietary AP3 precision medicine platform to develop precision oncology medicines. The company is also advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, in a potentially registrational Phase 2 trial for endometrial cancer.
References
[1] https://www.globenewswire.com/news-release/2025/04/25/3068264/0/en/Acrivon-Therapeutics-to-Reveal-the-Molecular-Mechanisms-Driving-Strong-Single-Agent-Activity-of-ACR-2316-its-AP3-Enabled-Clinical-Stage-WEE1-PKMYT1-Inhibitor-at-the-AACR-Annual-Mee.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet